TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects with type 2 diabetes between the age of 20-75 years who can speak and understand Arabic or English~* Female subjects with type 2 diabetes between the age of 20-75 years who can speak and understand Arabic or English~* Patients must be on any basal insulin (once daily)~* Patients must be on any basal insulin (twice daily)~* Patients on stable dose of oral antidiabetes drugs can be included (No change in the dose for the previous 12 weeks)~* Body Mass Index \<40kg/m2~* Subjects who have signed informed consent form~* Patients will be fasting during Ramadan~Exclusion Criteria:~* Type 1 diabetes~* Type 2 diabetes on a basal bolus regimen or those on premix insulin or on self-mix insulin~* On GLP-1 receptor agonists medication~* On glinide medication~* Ischaemic heart disease~* Left bundle branch block on ECG~* Active diabetic retinopathy or maculopathy requiring acute treatment~* Unwilling to follow the protocol~* Pregnancy, intention to become pregnant, breastfeeding

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Insulin glargine U100 (Type: ACTIVE_COMPARATOR): Intervention: half of the subjects will be randomised to insulin glargine U100 basal insulin treatment (or continued on glargine if already treated) that will be administered daily in the evening
- insulin degludec U100 (Type: ACTIVE_COMPARATOR): Intervention: half of the subjects will be randomised to insulin degludec U100 basal insulin treatment that will be administered daily in the evening

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Albumin Administration in Cirrhotic Patients With Bacterial Infection and a Systemic Inflammatory Response Syndrome Unrelated to Spontaneous Bacterial Peritonitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cirrhosis defined by clinical, laboratory or ultrasonographic findings~* Child-Pugh \> 8~* Sepsis defined by the presence of proved or suspected infection with two of the four SIRS (systemic inflammatory response syndrome) criteria (Wong F, et al. Sepsis in cirrhosis: report on the 7th meeting of the international ascites club. Gut 2005)~* Creatinine \< 160 µmol/L~* Written informed consent~* Absence of the exclusion criteria~Exclusion Criteria:~* Spontaneous bacterial peritonitis~* Difficult to treat infections such as : endocarditis, septic arthritis, osteomyelitis~* Heart insufficiency (YHA III-IV)~* Digestive bleeding during the week preceding the study~* Septic shock~* Hepatocellular carcinoma : stage D~* Use of antibiotics during the week preceding the study, except noroxin used for long-term antibioprophylaxy~* Diseases which can influence the short term survival

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Usual treatment (Type: NO_INTERVENTION): intravenous injection of Human Albumin. 1,5g/kg on first day and 1g/kg on third day
- Human Albumin (Type: EXPERIMENTAL): 1,5g/kg on first day and 1g/kg on third day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Studies With 1,25-Dihydroxycholecalciferol

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Patients with hereditary resistance to calcitrol.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Drug treatment (Type: EXPERIMENTAL): 1,25-Dihydroxycholecalciferol 5 ug orally per day for 2 years

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Untreated, histologically confirmed, KRAS wild type, resectable gastric or esophageal adenocarcinoma~* T2-4 NX M0 disease~* ECOG performance status 0-1~* adequate hematological status~* adequate renal function~* adequate hepatic function~* adequate metabolic function~Exclusion Criteria:~* pregnant or breast feeding women~* previous malignancy other than gastric cancer in the last 5 years except curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix~* arterial or venous thromboembolism within 6 months before enrollment~* clinically significant cardiovascular disease within 1 year before enrollment~* history of interstitial lung disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- treatment (Type: EXPERIMENTAL): 3 cycles(repeated q21d) Epirubicine 50mg/m² i.v. d1 Oxaliplatin 100mg/m² i.v. d1 Capecitabine 500mg/m² bid d1-d21 Panitumumab 9mg/kg i.v. d1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Mitochondrial Oxygraphy on Subcutaneous and Peri-visceral Adipose Tissue: Influence of Body Composition

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing oncological, bariatric, parietal surgery~* Patients able to give an informed consent~* Patients affiliated to an Health Care insurance~* Patients aged over 18~Exclusion Criteria:~* Patients under guardianship, curatorship or deprived of freedom~* Pregnant or breastfeeding women~* Participation refusal~* Patients under chemotherapy~* Patients with peritonitis and infectious parietal processes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All patients (Type: EXPERIMENTAL): a sample of adipose tissue will be collected during the scheduled surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound-induced Adipose Tissue Cavitation and Training in Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male/female (1:1),~* age 18-65 y,~* abdominal obesity (waist circumference \>102cm or \>88cm) -~Exclusion Criteria:~* involvement in dietary or exercise intervention in the last year,~* intake of any medication,~* clinically diagnosed diseases (cardiovascular disease, hypertension, venous thromboses blood diseases, presence of a pacemaker/defibrillator, brain or nervous system diseases, kidney, thyroid or liver disease, chronic inflammatory diseases, cancer, osteoporosis and epilepsy).~* Persons with a pregnancy,~* a recent bone injury or the presence of a metal prothese

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Exercise training + adipose tissue cavitation (Type: EXPERIMENTAL): None
- Exercise training + sham procedure (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: HAART Annuloplasty Device Valve Repair Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The patient underwent or is undergoing aortic valve repair using either the HAART 300 or HAART 200 Aortic Annuloplasty Device in accordance with the Instructions for Use.~* The patient has reviewed and signed the written informed consent form.~* The patient agrees to return for all follow-up evaluations for the duration of the study.~Exclusion Criteria:~* Retrospective patient that has undergone a subsequent aortic valve replacement procedure.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HAART 300 (Type: None): HAART 300 Aortic Annuloplasty Device
- HAART 200 (Type: None): HAART 200 Aortic Annuloplasty Device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Multimodal Pain Management Following Primary TKA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 40 Years Old~* Scheduled for Primary Total Knee Arthroplasty~Exclusion Criteria:~* Opiate Tolerant (≥60mg/day oral morphine/equivalent for ≥1 week)~* Neuromuscular deficit affecting the lower limbs~  * Peripheral neuropathy~ * Radiculopathy/Sciatica~* Known allergy or intolerance to Bupivacaine or Ropivacaine~* Hepatic Disease~* Renal Disease/Patients needing Dialysis~* Planned unicompartmental knee replacement~* Less than 90 degree of knee flexion preoperatively.~* Patients who lack the capacity to consent or are unwilling to do so~* At the discretion of the PI, patients who may have difficulty complying with standard of care (SOC) followup may also be excluded

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- liposomal bupivacaine (LB) (Exparel) (Type: ACTIVE_COMPARATOR): Mixture of 50 milliliters (mL) of 0.25% Bupivacaine with epinephrine, 40 mL of sterile saline and 20 mL of Exparel®.
- Ropivacaine cocktail (PIC) (Type: ACTIVE_COMPARATOR): 400 milligrams (mg) Ropivacaine, 5 mg morphine, and 0.4 mg epinephrine in 100 cc solution
- continuous femoral nerve blocks (cFNB) (Type: ACTIVE_COMPARATOR): Continuous Femoral Nerve Block- 0.25% Bupivacaine at a rate of 5 ml/hour for 48 Hours.~Sciatic nerve block - 0.125% bupivacaine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Impact of Welding Fumes on the Arterial System : RISCAS Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female ≥ 18 years~* Employee performing welding or airport operations~* free, informed and written consent~* Being affiliated to a social security system~Exclusion Criteria:~* Taking cardiovascular medications which modify endothelial function and / or coagulation (antiplatelet, antihypertensive, cardiotropic).~* People with a history of ischemic cardiovascular disease, thrombotic disease, chronic inflammatory disease~* Pregnant women~* People with health status would be likely, in the baseline state, to have parameters studied in the study disrupted.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- welder/airport agent (Type: EXPERIMENTAL): No drug and no placebo were used in this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Photon/Proton Radiation Therapy for Carcinoma of the Skin of the Head and Neck

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Carcinoma of the skin of the head and neck region with incidental or symptomatic perineural invasion.~* Biopsy-proven squamous cell carcinoma.~* Will receive treatment with proton radiation.~Exclusion Criteria:~* Evidence of distant metastasis.~* Previous irradiation for head and neck cancer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Photon/Proton Radiation Therapy (Type: None): Data consolidation and analysis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Peri-surgical Results at Short and Mean Terms of the GORE ® Excluder Iliac Branch Endoprosthesis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* High surgical risk:~  * Comorbidity cardiopulmonary~ * Renal insufficiency~ * Hostile abdomen including ascites or portal hypertension~* Anatomic criteria:~  * Primitive iliac aneurysm superior to 25 mm without collar~ * Primitive iliac length superior to 40 mm~ * Primitive iliac distal diameter superior to 14 mm~ * Presence of internal iliac collar~* Affiliation to a social security system~Exclusion Criteria:~* Patient without surgical risk~* Non-respect of the Anatomic criteria~* Patient with known allergy to the materials of the device~* Patient with systemic infection~* Patient with severe renal insufficiency~* Patient unable to complete the oximetry test~* Persons under legal protection

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GORE Excluder (Type: EXPERIMENTAL): GORE Excluder Iliac Branch Endoprosthesis arm with 'ILIAC ENDOPROSTHESIS GORE EXCLUDER'

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Innovative Occupational Program Using New Technologies (KODRO) Life of Nursing

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Nursing home residents~Exclusion Criteria:~* Not able to participate in the ocupational therapy using KODRO (Demential end of life ...)

- Gender: ALL
- Minimum Age: 65 Months
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Stimulating activities with the use of tactile tablet computer (Type: None): Stimulating activities through the use of a tactile tablet computer. These tablets are linked to an internet-based service platform and offer a very easy and intuitive interaction for the user, even when this person is suffering from a moderate cognitive and/or physical impairment.
- Stimulating activities with usual stimulation activity program (Type: None): No Stimulating activities through the use of a tactile tablet computer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Interventional Study Collecting Quantitative and Qualitative Data About Patient With Non Treated Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age ≥ 18 years~* oral cavity cancer, oropharynx cancer, hypopharynx cancer, larynx cancer~* non treated cancer~* patient informed of his diagnosis~* speak fluent french~* patient covered by health insurance~* signed informed consent~Inclusion Criteria for interviewed  patients :~* no speech troubles~* patient consents being recorded~Exclusion Criteria:~* history of cancer~* psychological history~* patient under guardianship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- questionnaires (Type: ACTIVE_COMPARATOR): 4 questionnaires to answer at baseline 45 minutes approx.
- interview (Type: EXPERIMENTAL): semi directive interview 105 patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: EScitalopram PIndolol ONset of Action

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patients aged between 18 and 65 years old~* patients suffering from major depression according to DSM-IV with a MADRS score of at least 25 and not treated by an antidepressant at the time of inclusion with the exception of non-responders to antidepressant for a period of at least 6 weeks or not tolerating an ongoing antidepressant necessitating a change of the antidepressant(excluding fluoxetine and irreversible MAOI)~* informed consent~Exclusion criteria:~* any other Axis I disorder excluding anxiety disorder not dominating the clinical picture, nicotine abuse~* non-responders to escitalopram in the past~* already taking pindolol~* pregnancy and breast feeding~* contraindication to one of the two treatments (medical conditions, drug treatments)~* significant somatic comorbidity interfering with the study procedures~* high risk of suicidality~* women of childbearing age not having a safe means of contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- escitalopram 20mg + pindolol 15mg (Type: EXPERIMENTAL): Days 1-2: escitalopram 10 mg + placebo, days 3-42: escitalopram 20mg + placebo Days 1-14: pindolol 15 mg, days 15-17: pindolol 7.5 mg
- Escitalopram 30 mg (Type: ACTIVE_COMPARATOR): Days 1-2: escitalopram 10 mg+ placebo, days 3-4 escitalopram 20 mg + placebo, days 5-42: escitalopram 30mg+ placebo
- escitalopram 20 mg (Type: ACTIVE_COMPARATOR): days 1-2: escitalopram 10 mg+ placebo, days 3-42: escitalopram 20 mg + placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have completed all scheduled visits in protocol 22003 and have shown they can adequately follow the protocol, with sufficient medical justification to continue on open-label treatment with STX209, as assessed by the principal investigator~Exclusion Criteria:~* Subjects with a medical condition that might interfere with the conduct of the study, confound interpretation of the study results, or endanger their own well-being.~* The occurrence or continuation of any adverse event or condition during study 22003 that, in the opinion of the Investigator, should exclude the subject from participating in this open-label extension

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- STX209 (Type: EXPERIMENTAL): STX209 (arbaclofen)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Type 1 or type 2 diabetes~* Diabetic macular edema~Exclusion criteria:~* Recent intra-ocular surgery in the study eye (e.g., cataract surgery in the last 6 months)~* Recent laser photocoagulation in the study eye~* Recent treatment with Avastin, Lucentis, or intravitreal corticosteroids in the study eye~Other protocol-defined inclusion/exclusion criteria applied

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Aliskiren 300 mg (Type: EXPERIMENTAL): Aliskiren 300 mg once daily for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Diagnostic Reasoning and Sense of Alarm at Dyspnoea and / or Chest Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients between 18 and 80 years~* Patients consulting on primary care for chest pain or dyspnea

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues